Skip to main content
. Author manuscript; available in PMC: 2020 Sep 5.
Published in final edited form as: Gynecol Oncol. 2016 Oct 19;143(3):650–654. doi: 10.1016/j.ygyno.2016.10.015

Fig. 3.

Fig. 3.

GRP78 expression in (A) treatment-naïve CAH EMB specimens show more GRP78 overexpression among endometrial lesions that progress to carcinoma or persist, and do not regress. (B) GRP78 overexpression is attenuated after progestin treatment with carcinoma and persistent CAH showing continued GRP78 overexpression compared with benign endometrial lesions and those without atypia.